Dr. Cooney is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
11100 Euclid Ave
Cleveland, OH 44106Phone+1 216-844-8500
Education & Training
Case Western Reserve University/University Hospitals Cleveland Medical CenterFellowship, Hematology and Medical Oncology, 2001 - 2004- Case Western Reserve University/University Hospitals Cleveland Medical CenterResidency, Internal Medicine, 1998 - 2001
Case Western Reserve University School of MedicineClass of 1998
Certifications & Licensure
OH State Medical License 2000 - 2025- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- Regional Top Doctor Castle Connolly, 2014
Clinical Trials
- Lenalidomide and Docetaxel in Treating Patients With Advanced Solid Tumors Start of enrollment: 2005 Jun 01
- Androgen Ablation Therapy With or Without Chemotherapy in Treating Patients With Metastatic Prostate Cancer Start of enrollment: 2006 Sep 26
- Treating Patients With Prostate Cancer That Did Not Respond to Hormone Therapy Start of enrollment: 2006 Sep 01
- Join now to see all
Publications & Presentations
PubMed
- 605 citationsChemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer: Long-Term Survival Analysis of the Randomized Phase III E3805 CHAARTED TrialChristos Kyriakopoulos, Yu-Hui Chen, Michael A. Carducci, Glenn Liu, David F. Jarrard
Journal of Clinical Oncology. 2018-01-31 - 1823 citationsChemohormonal Therapy in Metastatic Hormone-Sensitive Prostate CancerChristopher Sweeney, Yu-Hui Chen, Michael A. Carducci, Glenn Liu, David F. Jarrard
The New England Journal of Medicine. 2015-08-19 - 13 citationsDetection of Alpha-Methylacyl-CoA Racemase (AMACR), a Biomarker of Prostate Cancer, in Patient Blood Samples Using a Nanoparticle Electrochemical BiosensorPo-Yuan Lin, Kai Lun Cheng, James McGuffin-Cawley, Fuh-Sheng Shieu, Anna Cristina S. Samia
Biosensors. 2012-09-26
Press Mentions
Chutes & Ladders—Doubling down on R&D, Daiichi Makes Changes to U.S. Research UnitMarch 1st, 2019
PAREXEL Expands Oncology Expertise Through FDA and Medical Oncologist AppointmentsFebruary 27th, 2019
Sermonix Pharmaceuticals Announces Article Comparing ‘Traditional’ to ‘Just-in-Time’ Trial Enrollment Models Is Published in JCO Clinical Cancer InformaticsJune 27th, 2023
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
